Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer
Ontology highlight
ABSTRACT: The goal of this prospective clinical trial is to evaluate efficacy and safety of irinotecan liposomes for first-line treatment of advanced colorectal cancer. The primary endpoint is Objective response rate (ORR) per RECIST 1.1. The secondary endpoints are overall survival (OS), progression-free survival (PFS), disease control rate (DCR) and safety based on NCI-CTCAE 5.0
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 68175 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA